The US Centers for Medicare and Medicaid Services must negotiate the prices of five more drugs in its second cycle than the first, and in three fewer months amid speculation the Trump Administration could “pause” the program to make changes.
Medicare Price Negotiation Round Two: New Administration, More Drugs, Less Time
Speculation that the Trump Administration may "pause" the second negotiation cycle to make changes to the program adds uncertainty to an already challenging scenario.
